## REDUCE AU Small Finance Bank

# Stress to persist in near term, but eyes glued on 1.6% RoA



BFSI - Banks > Result Update > January 25, 2025

**TARGET PRICE (Rs): 625** 

AU SFB logged a muted performance with a 5% miss on PAT at Rs5.3bn/RoA at 1.5%, mainly on lower other income and elevated provisions owing to ongoing stress in unsecured loans (MFI, Cards, PL) and seasonality impact on the agri and wheels book. The management indicated that 20% of the MFI portfolio (MFI book is 7% of overall loans) will be impacted by the MFIN 2.0 guidelines, and thus expects higher slippages/credit cost in Q4. The bank has taken corrective measures in the Card business, but stress could remain elevated in 4Q. Given the strain in the unsecured portfolio, the bank plans to accelerate portfolio realignment toward secured loans, while we believe it should benefit from a policy rate cut on the margin front. Factoring in the Q3 earnings miss and higher LLP, we cut FY25-27E earnings by 3-5%, while we expect the bank to deliver 1.6-1.7% RoA. We retain REDUCE and TP of Rs625, rolling forward on 2.2x Dec-26E ABV, and await more clarity on asset quality and the Universal Bank license.

AU Small Finance Bank: Financial Snapshot (Standalone)												
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E							
Net profit	14,279	15,347	21,215	27,939	35,009							
Loan growth (%)	26.7	25.2	45.2	23.7	25.7							
NII growth (%)	36.8	16.5	56.0	31.8	25.1							
NIM (%)	5.7	5.3	6.4	6.4	6.5							
PPOP growth (%)	11.3	20.7	87.6	27.2	27.8							
Adj. EPS (Rs)	21.4	22.9	28.5	37.5	47.0							
Adj. EPS growth (%)	19.4	7.1	24.3	31.7	25.3							
Adj. BV (INR)	161.4	183.2	215.8	250.1	294.0							
Adj. BVPS growth (%)	39.1	13.5	17.8	15.9	17.6							
RoA (%)	1.8	1.5	1.6	1.6	1.7							
RoE (%)	15.4	13.0	14.5	15.4	16.6							
P/E (x)	27.7	25.9	20.8	15.8	12.6							
P/ABV (x)	3.7	3.2	2.8	2.4	2.0							

Source: Company, Emkay Research; Note: Merged Financials from FY25 onwards

# Healthy growth aided by secured assets; margin dipped QoQ due to interest reversal

AU SFB posted a healthy credit growth of 28% YoY/5% QoQ (on merged basis), driven by continued traction seen in the wheels segment (39% YoY/10% QoQ), mortgages book (5% QoQ), and wholesale book (36% YoY/6.4% QoQ). However, the unsecured book (MFI/PL/CC) remains muted at 5% QoQ amid stress in the industry's unsecured book. Overall deposit growth moderated to 25% YoY/2.3% QoQ, mainly due to decline in CASA, which saw outflow from the government account. This, coupled with change in portfolio mix (9bps), interest reversal (4bps), and 12% higher average investment book (10bps), led to contraction in NIM by 20bps to 5.9% while the mgmt. indicates full-year NIM guidance of  $\sim$ 6%. Further, the management expects GLP growth of 20%, led by secured asset growth of 23-25% and unsecured asset de-growth of 10%.

# Elevated stress in unsecured loans and seasonality impact on agri/wheels book leads to higher NPAs in 3Q

Fresh slippages were elevated at Rs9.6bn/5.7% of loans, mainly owing to ongoing stress in unsecured assets and seasonal impact on the agri and wheels book. This led to increase in GNPA/NNPA ratios to 2.3%/0.9%, resp, during 3Q. The management has indicated that 20% of the portfolio is impacted by the MFIN 2.0 guidelines, while ~17% of the borrowers have taken loans from more than 3 lenders, and the remainder have total unsecured exposure above-Rs0.2mn. The bank expects MFI slippages to remain elevated in 4Q, as also the credit cost. In the Credit card book, elevated stress was mainly due to the bank's contingency on digital underwriting with not enough guards, incl higher revolver portfolio. The bank expects card portfolio stress to stay elevated in 4Q too.

## We retain REDUCE on AU SFB

Factoring in the 3Q earnings miss and higher LLP, we cut FY25-27E earnings by 3-5%, and expect the bank to deliver 1.6-1.7% RoA. We retain REDUCE on the stock, with unchanged TP of Rs625, rolling forward on 2.2x Dec-26E ABV. Separately, the bank has applied for a Universal Banking license, which it is hopeful of receiving from the RBI in due course; if this happens, it should ease the restrictions under the SFB framework.

Target Price - 12M	Dec-25
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	5.1
CMP (24-Jan-25) (Rs)	594.7

Stock Data	Ticker
52-week High (Rs)	755
52-week Low (Rs)	534
Shares outstanding (mn)	744.2
Market-cap (Rs bn)	443
Market-cap (USD mn)	5,134
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	1,486.4
ADTV-3M (USD mn)	17.2
Free float (%)	72.0
Nifty-50	23,092
INR/USD	86.2
Shareholding, Sep-24	
Promoters (%)	22.9
FPIs/MFs (%)	40.7/20.1

Price Performance											
(%)	1M	3M	12M								
Absolute	6.9	(7.9)	(19.3)								
Rel. to Nifty	9.9	(2.7)	(25.1)								

## 1-Year share price trend (Rs)



#### Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

## Nikhil Vaishnav


nikhil.vaishnav@emkayglobal.com +91 22 6624 2485

### Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275


## **Story in Charts**

Exhibit 1: AUM growth remains healthy, led by secured assets; deposit growth dipped owing to decline in CASA




Source: Company, Emkay Research; Note: The figures are adjusted for the Fincare merger impact

Exhibit 3: NIM dipped to 5.9% led by portfolio mix, higher CoF, interest reversal, and higher investment book




Source: Company, Emkay Research; Note: 1QFY25 numbers include the Fincare merger impact

Exhibit 5: NPAs inch up due to stress in MFI and Cards as well as owing to the seasonal rise in slippages in the wheels and agri book




Source: Company, Emkay Research

Exhibit 7: We expect RoA to settle at around 1.6% over FY25-26E, before improving to 1.7% in FY27E




Source: Company, Emkay Research

Exhibit 2: AUM mix remains dominated by Wheels and SBL; MFI share stands at  $\sim\!7\%$ 




Source: Company, Emkay Research

Exhibit 4: CASA dipped owing to outflow in the government account, while TD growth remains healthy




Source: Company, Emkay Research; Note: 1QFY25 numbers include the Fincare merger impact

Exhibit 6: Product-wise GNPA – Higher stress in unsecured products as well as marginal rise in HL/SBL MSME



Source: Company, Emkay Research

Exhibit 8: The stock trades at 2.8x one-year forward P/ABV



Source: Company, Emkay Research

## **Exhibit 9: Actuals vs. Estimates (Q3FY25)**

(Rs mn)	Actuals		imates	Va	riation	Comments
		Consensus				
Net income	26,411	28,063	26,429	-6%	0%	Decline in NIM and lower other income led to a miss
PPOP	12,049	12,241	11,264	-2%	7%	Lower net income and contained opex led to a PPoP miss
PAT	5,284	5,566	5,186	-5%	2%	Decline in PPOP and higher LLP led to a PAT miss

Source: Company, Emkay Research

**Exhibit 10: Quarterly Summary** 

(Rs mn)	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	YoY (%)	QoQ (%)	FY24A	FY25E	YoY (%)
Interest Earned	27,358	28,295	37,690	39,106	41,135	50	5	105,547	161,319	53
Interest Expenses	14,109	14,925	18,485	19,363	20,908	48	8	53,976	80,853	50
Net Interest Income	13,249	13,370	19,206	19,743	20,227	53	2	51,571	80,466	56
Global NIMs (reported)	5.48	5.10	6.00	6.10	5.90	42bps	-20bps	5.32	6.36	104bps
Non-interest Income	4,497	5,556	5,457	6,380	6,184	38	-3	17,458	24,175	38
Operating Expenses	11,175	12,285	14,781	14,806	14,362	29	-3	44,647	58,894	32
Pre-Provisioning Profit	6,571	6,642	9,881	11,317	12,049	83	6	24,382	45,747	88
Provision & Contingencies	1,589	1,325	3,192	3,730	5,017	216	35	4,388	17,536	300
PBT	4,981	5,316	6,689	7,588	7,032	41	-7	19,994	28,211	41
Income Tax Expense (Gain)	1,229	841	1,663	1,876	1,748	42	-7	4,647	6,996	51
Net Profit/(Loss)	3,752	3,707	5,026	5,712	5,284	41	-7	15,347	21,215	38
Gross NPA (%)	1.98	1.67	1.78	1.98	2.31	33bps	33bps	1.67	2.33	66bps
Net NPA (%)	0.68	0.55	0.63	0.75	0.91	23bps	16bps	0.55	0.90	35bps
Deposits (Rs bn)	801	872	973	1,097	1,123	40	2	872	1,186	36
Net Advances (Rs bn)	667	732	897	948	996	49	5	732	1,062	45

Source: Company, Emkay Research

**Exhibit 11: Key Assumptions** 

(%)	FY24A	FY25E	FY26E	FY27E
AUM Growth	25.2	53.0	23.0	25.0
Deposit Growth	9.0	34.0	25.9	28.3
NIM	5.3	6.4	6.4	6.5
GNPA	1.7	2.3	2.2	2.2
Credit Cost	0.7	1.9	1.7	1.8

Source: Emkay Research

**Exhibit 12: Key Ratios and Trends** 

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Loans (Rs mn)	634,298	671,240	726,601	746,380	780,387	855,207	896,520	948,382	995,590
Growth YoY (%)	50.9	40.3	30.6	26.3	23.0	27.4	23.4	27.1	27.6
Growth QoQ (%)	7.3	5.8	8.2	2.7	4.6	9.6	4.8	5.8	5.0
Composition (%)									
Corporate	19	21	21	22	24	24	19	20	21
Retail and Treasury	81	79	79	78	76	76	81	80	79
Liability Profile									
Deposits (Rs mn)	684,511	773,981	780,582	851,961	898,540	977,031	972,900	1,096,931	1,122,600
Growth YoY (%)	54.6	47.2	27.6	31.1	31.3	26.2	24.6	28.8	24.9
Growth QoQ (%)	5.3	13.1	0.9	9.1	5.5	8.7	(0.4)	12.7	2.3
CASA (%)	34.3	34.4	31.1	29.4	29.4	29.8	32.0	32.4	30.6
CA (%)	4.1	4.8	4.2	4.8	4.5	4.1	4.2	5.5	4.9
SA (%)	30.2	29.7	27.0	24.6	25.0	25.7	27.9	26.9	25.7
No. of Branches	1,015	1,027	1,038	1,042	1,049	1,133	2,414	2,408	2,400
NIM (%)	6.2	6.1	5.7	5.5	5.5	5.1	6.0	6.1	5.9
Asset Quality									
GNPA (%)	1.8	1.7	1.8	1.9	2.0	1.7	1.8	2.0	2.3
NNPA (%)	0.5	0.4	0.6	0.6	0.7	0.5	0.6	0.7	0.9
PCR (%)	72.1	75.0	69.0	69.1	66.0	67.6	65.1	62.8	61.2
Slippages (Rs mn)	2,310	1,910	3,170	3,490	4,030	2,960	5,430	7,360	9,560
Slippages – Annualized (%)	2.2	1.6	2.3	2.4	2.5	1.8	3.0	3.9	4.9
CAR (%)	22.0	23.6	21.5	22.4	20.8	20.1	20.1	18.5	18.0
Tier I (%)	20.0	21.8	20.7	21.0	19.1	18.8	18.9	17.4	16.9
ROE Decomposition (on total assets)									
NII (%)	5.8	5.7	5.5	5.3	5.4	5.1	6.5	6.0	5.7
Other Income (Ex. Treasury; %)	1.5	1.6	1.3	1.8	1.8	2.1	1.8	1.7	1.6
Opex (%)	4.5	4.6	4.5	4.4	4.5	4.7	5.0	4.5	4.1
PPOP (%)	2.8	2.7	2.4	2.8	2.7	2.5	3.4	3.4	3.4
Provisioning Cost (%)	0.2	0.2	0.1	0.5	0.6	0.5	1.1	1.1	1.4
PBT (%)	2.6	2.5	2.3	2.3	2.0	2.0	2.3	2.3	2.0
Tax (%)	0.7	0.5	0.6	0.6	0.5	0.3	0.6	0.6	0.5
ROA (%)	1.98	1.99	1.70	1.71	1.52	1.41	1.71	1.73	1.50
ROE (%)	15.2	15.8	13.8	13.9	12.5	12.0	14.3	14.5	13.0

Source: Company, Emkay Research; Note: Advances and Deposit figures for the past years are adjusted for the merger impact

## **AU Small Finance Bank: Standalone Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	82,054	105,547	161,319	205,526	249,588
Interest Expense	37,801	53,976	80,853	99,471	116,864
Net interest income	44,253	51,571	80,466	106,056	132,724
NII growth (%)	36.8	16.5	56.0	31.8	25.1
Other income	10,345	17,458	24,175	28,625	34,397
Total Income	54,597	69,029	104,641	134,681	167,121
Operating expenses	34,403	44,647	58,894	76,495	92,778
PPOP	20,195	24,382	45,747	58,186	74,343
PPOP growth (%)	11.3	20.7	87.6	27.2	27.8
Core PPOP	20,638	23,864	44,088	55,787	71,345
Provisions & contingencies	1,548	4,388	17,536	20,834	27,539
PBT	18,646	19,994	28,211	37,351	46,804
Extraordinary items	0	0	0	0	0
Tax expense	4,367	4,647	6,996	9,413	11,794
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	14,279	15,347	21,215	27,939	35,009
PAT growth (%)	26.4	7.5	38.2	31.7	25.3
Adjusted PAT	14,279	15,347	21,215	27,939	35,009
Diluted EPS (Rs)	21.4	22.9	28.5	37.5	47.0
Diluted EPS growth (%)	19.4	7.1	24.3	31.7	25.3
DPS (Rs)	1.0	1.0	2.0	2.5	2.5
Dividend payout (%)	4.7	4.4	7.0	6.7	5.3
Effective tax rate (%)	23.4	23.2	24.8	25.2	25.2
Net interest margins (%)	5.7	5.3	6.4	6.4	6.5
Cost-income ratio (%)	63.0	64.7	56.3	56.8	55.5
Shares outstanding (mn)	666.7	669.2	744.2	744.2	744.2

Source:	Company,	Emkay I	Research ,	: Note :	Merged	Financials i	from FY25	onwards

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	6,667	6,692	7,442	7,442	7,442
Reserves & surplus	103,106	118,903	160,353	186,431	219,580
Net worth	109,773	125,595	167,795	193,874	227,022
Deposits	693,650	871,821	1,185,987	1,493,448	1,916,724
Borrowings	52,987	54,794	99,358	110,369	108,688
Interest bearing liab.	746,636	926,615	1,285,345	1,603,817	2,025,412
Other liabilities & prov.	45,751	42,046	65,401	79,118	100,498
Total liabilities & equity	902,161	1,094,256	1,518,541	1,876,808	2,352,932
Net advances	584,215	731,627	1,062,477	1,313,949	1,651,314
Investments	200,720	271,334	339,606	420,421	525,074
Cash, other balances	94,252	63,763	77,121	96,229	121,525
Interest earning assets	879,187	1,066,723	1,479,203	1,830,599	2,297,913
Fixed assets	7,401	8,516	11,768	15,139	19,509
Other assets	15,573	19,017	27,570	31,071	35,510
Total assets	902,161	1,094,256	1,518,541	1,876,808	2,352,932
BVPS (Rs)	164.6	187.7	225.5	260.5	305.0
Adj. BVPS (INR)	161.4	183.2	215.8	250.1	294.0
Gross advances	529,527	665,575	909,031	1,205,647	1,505,124
Credit to deposit (%)	84.2	83.9	89.6	88.0	86.2
CASA ratio (%)	38.4	34.4	29.0	28.4	28.6
Cost of deposits (%)	5.5	6.3	6.8	6.4	6.0
Loans-to-Assets (%)	64.8	66.9	70.0	70.0	70.2
Net advances growth (%)	26.7	25.2	45.2	23.7	25.7
Deposit growth (%)	31.9	27.6	34.0	25.9	28.3
Book value growth (%)	38.0	14.0	20.1	15.5	17.:

Asset quality and other metrics													
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E								
Asset quality													
Gross NPLs	9,813.1	12,363.1	25,165.5	29,640.0	36,742.4								
Net NPLs	2,861.6	4,006.4	9,562.9	10,374.0	11,022.7								
GNPA ratio (%)	1.7	1.7	2.3	2.2	2.2								
NNPA ratio (%)	0.5	0.5	0.9	0.8	0.7								
Provision coverage (%)	70.8	67.6	62.0	65.0	70.0								
Gross slippages	12,398.8	13,650.0	31,181.4	29,830.2	35,512.1								
Gross slippage ratio (%)	2.1	1.8	2.7	2.1	2.0								
LLP ratio (%)	0.5	0.8	1.9	1.7	1.8								
NNPA to networth (%)	2.5	3.1	5.6	5.2	4.7								
Capital adequacy													
Total CAR (%)	23.7	20.4	21.2	19.9	18.7								
Tier-1 (%)	21.9	19.1	19.7	18.5	17.3								
CET-1 (%)	21.9	19.1	19.7	18.5	17.3								
RWA-to-Total Assets (%)	53.8	58.5	55.0	55.0	55.0								
Miscellaneous													
Total income growth (%)	33.6	33.1	50.8	26.2	21.3								
Opex growth (%)	42.6	29.8	31.9	29.9	21.3								
Core PPOP growth (%)	23.4	15.6	84.7	26.5	27.9								
PPOP margin (%)	21.9	19.8	24.7	24.8	26.2								
PAT/PPOP (%)	70.7	62.9	46.4	48.0	47.1								
LLP-to-Core PPOP (%)	7.5	18.4	39.8	37.3	38.6								
Yield on advances (%)	13.1	12.8	15.0	14.7	14.4								
Cost of funds (%)	5.7	6.5	7.3	6.9	6.4								

Source: Company, Emka	v Research : Note .	: Merged Financials fro	om FY25 onwards

Valuations and key l	Ratios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	27.7	25.9	20.8	15.8	12.6
P/B (x)	3.6	3.2	2.6	2.3	1.9
P/ABV (x)	3.7	3.2	2.8	2.4	2.0
P/PPOP (x)	19.6	16.3	9.7	7.6	5.9
Dividend yield (%)	0.2	0.2	0.3	0.4	0.4
DuPont-RoE split (%)					
NII/avg assets	5.6	5.2	6.2	6.2	6.3
Other income	1.3	1.7	1.9	1.7	1.6
Fee income	1.4	1.7	1.7	1.5	1.5
Opex	4.3	4.5	4.5	4.5	4.4
PPOP	2.5	2.4	3.5	3.4	3.5
Core PPOP	2.6	2.4	3.4	3.3	3.4
Provisions	0.2	0.4	1.3	1.2	1.3
Tax expense	0.5	0.5	0.5	0.6	0.6
RoA (%)	1.8	1.5	1.6	1.6	1.7
Leverage ratio (x)	8.6	8.5	8.9	9.4	10.0
RoE (%)	15.4	13.0	14.5	15.4	16.6
Quarterly data					
Rs mn, Y/E Mar	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
NII	17,612	17,979	19,206	19,743	20,227
NIM (%)	6.4	6.1	6.2	6.1	5.9
PPOP	8,444	8,306	9,515	11,317	12,049
PAT	4,642	5,347	5,016	5,712	5,284
EPS (Rs)	6.96	8.02	7.52	8.57	7.93

Source: Company, Emkay Research; Note: Merged Financials from FY25 onwards

## **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
23-Oct-24	652	625	Reduce	Anand Dama
26-Jul-24	650	625	Reduce	Anand Dama
26-Apr-24	600	600	Reduce	Anand Dama
19-Mar-24	560	600	Reduce	Anand Dama
28-Jan-24	708	625	Reduce	Anand Dama
30-Nov-23	741	650	Reduce	Anand Dama
06-Nov-23	674	650	Hold	Anand Dama
30-Oct-23	666	650	Hold	Anand Dama
23-Jul-23	767	730	Hold	Anand Dama
26-Apr-23	643	700	Hold	Anand Dama
09-Mar-23	624	650	Hold	Anand Dama
20-Jan-23	616	650	Hold	Anand Dama
19-Oct-22	626	650	Hold	Anand Dama
21-Jul-22	587	630	Hold	Anand Dama
30-Jun-22	592	650	Hold	Anand Dama
27-Apr-22	681	670	Hold	Anand Dama
11-Feb-22	660	638	Hold	Anand Dama
29-Jan-22	636	638	Hold	Anand Dama

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk D

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of January 25, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of January 25, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 25, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 3. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.